How to register a veterinary medicinal product in Ukraine: procedure and requirements of the new Regulation (CMU Resolution No. 1206)

Since 7 October 2026, the state registration (marketing authorisation) of veterinary medicinal products in Ukraine has been carried out under the Regulation approved by Cabinet of Ministers Resolution No. 1206 of 30 September 2026. The Regulation sets out the content of the application and the registration dossier, the assessment procedure and timelines, and the labelling and package leaflet requirements, aligned with Regulation (EU) 2019/6. This article gives an overview of the procedure and requirements for specialists preparing registration documents. Some requirements, including those on GMP, GLP and GCP, apply after transitional periods.

The Regulation was adopted pursuant to Article 55(23) of the Law of Ukraine "On Veterinary Medicine and Animal Welfare", in force since 1 March 2026. It replaced Resolution No. 1349 of 21 November 2007, which governed the registration of veterinary preparations together with feed additives, premixes and compound feed, as well as Resolution No. 235 of 17 March 2023 on the National Institution of Ukraine for Veterinary Preparations and Feed Additives.

The document consists of the main text and three annexes: requirements for the application, for the registration dossier and for the package leaflet. The largest is Annex 2, which describes in detail the quality, safety, residue and efficacy documentation, separately for pharmaceutical and immunological products.

The Regulation does not apply, in particular, to products intended for research, products based on radioactive isotopes, and non-prescription products intended exclusively for aquarium and pond animals, ornamental fish, cage birds, homing pigeons, terrarium animals, small rodents, ferrets and pet rabbits, where such animals are kept as pets and are not food-producing animals.

What the applicant submits

The application is submitted to the State Service of Ukraine on Food Safety and Consumer Protection (SSUFSCP) by the holder of the registration dossier or its authorised representative. The application is accompanied by:

  • the registration dossier;
  • a summary of the pharmacovigilance system master file;
  • documents confirming that the manufacturing sites comply with good manufacturing practice requirements (approved by the Ministry of Agrarian Policy and Food or recognised in Ukraine as equivalent);
  • a document confirming the authority of the representative, if the application is submitted by a representative.

For certain categories the list is extended. For antimicrobial products, documents on the risks to human and animal health and the environment and a description of measures to limit the development of resistance are required. If a product for food-producing animals contains an active substance for which no maximum residue limits have been established, confirmation that an application to establish them has been submitted must be attached. Separate lists apply to homeopathic products and products containing genetically modified organisms.

The default form of submission is electronic, with a qualified electronic signature, via the SSUFSCP information and communication system, by e-mail or via the Unified State Web Portal of Electronic Services. The format of the electronic dossier is approved by the Ministry of Agrarian Policy and Food. Until 1 March 2030, documents may also be submitted on paper. The applicant is responsible for the accuracy and currency of the information submitted.

Key change: the applicant and the MAH must be a Ukrainian person

Under the Law, the applicant and the registration certificate holder (marketing authorisation holder, MAH) may only be a person "established and registered in Ukraine in accordance with the legislation of Ukraine" (Article 1(1)(29) and Article 55(2)). A foreign company, whether the manufacturer or the holder of the registration dossier, cannot submit the application or hold the registration certificate in its own name.

For a foreign product, the question of authorisation must therefore be settled before submission. The dossier holder appoints a Ukrainian person (for example, a subsidiary or a partner) who will submit the application and become the registration certificate holder, and concludes an authorisation agreement with it. A document confirming the authority of the dossier holder's representative is attached to the application. The agreement should also allocate responsibilities after registration, since it is the registration certificate holder who is responsible, among other things, for pharmacovigilance, labelling and keeping the information up to date.

This requirement also applies to products registered under the previous law: to obtain an unlimited registration, their dossier must be brought into line with the Law, "including the requirements for the registration certificate holder".

What the application contains

The application is drawn up in Ukrainian. Its content is set out in Annex 1 to the Regulation, and the same information forms the dossier summary:

  1. Type of product, with a reference to the article of the Law under which the applicant seeks registration (full dossier, generic, hybrid, combination, etc.).
  2. Details of the applicant, manufacturers and importers of the finished product and active substances, and a list of the sites involved in manufacturing, import, control and batch release.
  3. Product identification: name and ATCvet code, active substances and solvents, strength (for immunological products, biological activity or titre), pharmaceutical form, route of administration, target species.
  4. Manufacturing and pharmacovigilance: details of the manufacturing and import licence or of the document confirming the compliance of the manufacturing site, and the reference number of the pharmacovigilance system master file, assigned by the applicant.
  5. Product information: the proposed summary of product characteristics (Article 55-1 of the Law), a description of the final presentation including packaging, and the texts of the immediate and outer packaging and the package leaflet.
  6. Registration history abroad (if any): countries where the product is authorised or where the authorisation was withdrawn, countries where an application was submitted or rejected, EU Member States where the product is on the market, and copies of the summaries of product characteristics approved in the EU. The application ends with a reasoned conclusion on quality, safety and efficacy.

Structure of the registration dossier

The dossier requirements are set out in Annex 2 to the Regulation. For products other than biologicals, the dossier consists of four parts:

Part Content
1. Dossier summary Information under Annex 1 and critical expert reports. For a product proposed for supply without prescription, a critical review justifying this classification
2. Quality documentation Physico-chemical, biological or microbiological data on the active substances and the finished product: composition, development, manufacturing process, quality control, stability
3. Safety documentation Safety testing (pharmacology, toxicology, user safety, environmental risk, development of resistance) and residue testing (residue depletion, analytical methods)
4. Efficacy documentation Pre-clinical studies and clinical trials, including dose determination and confirmation and target animal tolerance

For biological products, including immunologicals, Annex 2 contains a separate Section III with its own requirements for starting materials, batch control and stability.

General requirements for preparing the dossier

  • Language. The dossier is drawn up in Ukrainian. Study (trial, test) results and bibliographic data may be submitted in English. An inaccurate translation is treated as a technical deficiency for which the application may be put on hold.
  • Format. At the applicant's choice, quality data may be submitted in the Common Technical Document (CTD) format; in that case the critical expert report on quality is based on the Quality Overall Summary (QOS). The electronic dossier format is approved by the Ministry of Agrarian Policy and Food.
  • Critical expert reports. They are signed and dated by the author and accompanied by information on the author's education and experience and a declaration of the author's professional relationship with the applicant. For Parts 3 and 4, the report includes a tabular summary of the data and cross-references to the technical documentation.
  • Pharmacopoeias and methods. The monographs of the State Pharmacopoeia of Ukraine, the European Pharmacopoeia or the official pharmacopoeia of an EU Member State apply. Non-pharmacopoeial methods must be justified, and control procedures described in enough detail to be reproduced, with validation results.
  • Good practices. The manufacture of active substances and the finished product must comply with GMP, pre-clinical studies with GLP and clinical trials with GCP (subject to transitional periods, see below). Animal experiments are carried out in line with the legislation on the protection of animals from cruelty.
  • Completeness. The dossier must include all information relevant to the assessment, both favourable and unfavourable, including data from incomplete or discontinued studies. It is prepared taking into account the guidelines agreed under Article 54(12) of the Law.

Specific types of products

State registration is valid for an unlimited period, with two exceptions. A registration granted under exceptional circumstances is valid for one year and a registration for a limited market for five years; both may be renewed. Such decisions state expressly that only a limited assessment was carried out because comprehensive data were not available.

The scope of the dossier and the procedure depend on the type of product (Sections IV–V of Annex 2):

  • Generics. Data are required showing the same qualitative and quantitative composition in active substances and the same pharmaceutical form as the reference product, together with bioequivalence data or a justification for their absence. For antimicrobial and antiparasitic substances, information on the level of resistance from the literature is provided; for intramuscular, subcutaneous and transdermal forms, data on residue depletion from the injection site and local tolerance. For biological products, the generic approach is generally not acceptable and the hybrid approach applies.
  • Hybrids. Parts 1 and 2 of the dossier are submitted in full, while the amount of new safety and efficacy data depends on the differences from the reference product.
  • Combination products. All four parts are completed, with a scientific justification of the combination and, as a rule, data on the fixed combination rather than on each active substance separately.
  • Informed consent. If the product is identical to one already registered and the holder of the rights to the data has consented to their use, the dossier contains only the information required under Annex 1.
  • Bibliographic (well-established use) applications. For active substances with well-established use, Parts 3 and 4 may be compiled from the scientific literature. The period of such use must be at least 10 years, and this approach does not apply to new therapeutic indications.
  • Limited market. Parts 1 and 2 are submitted in full; some of the data for Parts 3 and 4 may be omitted.
  • Exceptional circumstances. The applicant completes Part 1 and justifies why the benefit of the immediate availability of the product outweighs the risk of incomplete data. Post-authorisation studies may be a condition of registration.
  • Antimicrobials. Documents on risks and resistance mitigation measures are attached. The decision may impose an obligation to conduct post-authorisation studies.
  • Vaccines. For vaccines against notifiable and exotic diseases, efficacy and safety may be assessed on the basis of pre-clinical data where vaccination is prohibited or clinical trials are not possible. A multi-strain dossier is allowed for inactivated vaccines against antigenically variable pathogens (one virus species or one bacterial genus), and reduced data requirements apply to vaccines based on a platform technology.
  • Export only. The applicant states this in the application, and the decision prohibits the use of the product in Ukraine.

How the registration procedure works

The procedure follows a clear sequence, with timelines at each stage:

  1. Acceptance of the application. The application is registered on the day of receipt. Within 15 calendar days, the SSUFSCP notifies the applicant that the documents have been received or that the application has been put on hold.
  2. Payment for the assessment. The dossier assessment is a paid service provided by an authorised institution within the SSUFSCP system. The applicant receives the amount and payment details together with the notice of receipt and must pay within 10 calendar days. The assessment does not start, and the timelines are suspended, until payment is made in full.
  3. Dossier assessment. The authorised institution checks the documents, assesses the quality, safety and efficacy of the product and draws up a conclusion on the benefit-risk balance. The report is sent to both the applicant and the SSUFSCP.
  4. Decision. The SSUFSCP takes the decision within 10 working days of receiving the report. Registration may be refused only on the basis of a negative report and on the grounds set out in the Law. The product receives a number in the format UA/VET/YY/NNNNN, which does not change when the dossier is varied, and its details are entered in the State Register of Veterinary Medicinal Products within three working days.

The maximum timelines are set by Article 55 of the Law, to which the Regulation refers:

Type of product Dossier assessment, days Registration overall, days
Original (full dossier) up to 180 up to 210
Generic, hybrid, combination; informed consent, bibliographic, exceptional circumstances up to 90 up to 120
Homeopathic up to 60 up to 90

The assessment period may be extended once, by no more than 90 days, at the reasoned request of the institution. The timelines are also suspended while the institution awaits samples or additional information it has requested.

Safeguards for the applicant

The Regulation sets out the interaction between the applicant and the regulator in detail, drawing on the Law "On Administrative Procedure":

  • in a notice putting the application on hold, each deficiency must be linked to a specific section or page of the document and to the provision breached; general or evaluative wording and references to non-binding documents are not allowed, otherwise the notice is considered unfounded;
  • putting the application on hold again after the deficiencies have been remedied is prohibited, and the notice itself may be appealed;
  • the period for remedying deficiencies depends on their nature: at least 20 days for technical errors (including inaccurate translation), at least 30 days for an incomplete dossier and at least 10 days for other deficiencies; at the applicant's request, the period may be extended by up to 30 days;
  • a request for additional information or samples must be sent no later than 30 days before the end of the assessment, contain an exhaustive list and a justification, and may not go beyond the dossier requirements;
  • information from the dossier is accessible only to authorised officials and may not be disclosed to third parties without the applicant's written consent.

Labelling and package leaflet

Labelling is in Ukrainian, and its text must match the text agreed in the positive assessment report. The requirements for the immediate and outer packaging are set by Articles 72 and 73 of the Law, and the Regulation adds technical details:

  • the x-height of the labelling text must be at least 1.2 mm;
  • promotional samples must bear the mandatory statement "Attention! This is a promotional sample";
  • the labelling of homeopathic products contains no therapeutic indications;
  • the registration certificate holder must keep the labelling in line with current scientific knowledge.

The package leaflet is also in Ukrainian and corresponds to the summary of product characteristics. Mandatory information includes the withdrawal period (even if it is zero), the contact details of the registration certificate holder for reporting suspected adverse events, and whether the product is subject to veterinary prescription. For practising veterinarians, this means a consistent and predictable set of information in every leaflet.

Transitional periods

The Resolution defers the requirements that are hardest to meet, so that registration does not stall until the necessary infrastructure is in place:

Requirement Does not apply until
Documents confirming the GMP compliance of manufacturing sites 30 June 2027
Mandatory electronic submission (paper allowed) 1 March 2030
GLP and GCP for studies; GMP and GDP for active substances 30 June 2032
Dossier requirements on genetically modified organisms entry into effect of Article 55(5) of the Law

The GMP deadline is aligned with the current wording of the Law, under which the relevant provisions apply from 1 July 2027. Draft Law No. 15058-d, adopted at first reading on 9 November 2026, provides for postponing these requirements to 1 July 2028.

Products registered under the previous law

The Regulation governs new registrations. The status of products registered under the 1992 Law "On Veterinary Medicine" is determined by the transitional provisions of the current Law:

  • the manufacture, import and placing on the market of such products are allowed for five years from 1 March 2026, provided that the registration certificate is valid;
  • they may be registered for an unlimited period without changing the certificate number, by supplementing the dossier to meet the requirements of the Law, under a procedure approved by the ministry;
  • a product that complied with the previous requirements as of 28 February 2026 may remain on the market until its certificate expires, even if its labelling or package leaflet does not yet meet the new requirements.

The registration status of a specific product can be checked in the Register of Veterinary Medicinal Products on the Alliance website.

Preparing for submission

Given the requirements of the Regulation, it is practical to prepare for registration in the following order:

  1. Determine the type of product and the article of the Law under which the application is submitted: the scope of the dossier and the assessment timeline depend on it.
  2. Determine the applicant and the registration certificate holder. Under the Law, this may only be a person established and registered in Ukraine. For a foreign product, the authorisation of a Ukrainian person must be agreed with the dossier holder in advance, and a document confirming the representative's authority prepared.
  3. Prepare the manufacturing and pharmacovigilance documents: the list of sites, GMP confirmation (not required until 30 June 2027), and the pharmacovigilance system master file summary with its reference number.
  4. Prepare the texts in Ukrainian and check the consistency of names, figures, dates and references between the application and the dossier: the Regulation names exactly these technical deficiencies as grounds for putting an application on hold.
  5. Prepare the proposed summary of product characteristics, labelling and package leaflet in line with Articles 55-1, 72 and 73 of the Law and Annex 3 to the Regulation.
  6. Choose the form of submission. Electronic submission requires the applicant's qualified electronic signature. A paper set (until 1 March 2030) is submitted with a list of documents, continuous page numbering and a line after the text of each document.
  7. Plan the payment for the assessment within 10 calendar days of the SSUFSCP notice: the assessment does not start without full payment.
  8. Ensure prompt responses to requests during the assessment: while the applicant prepares additional information or samples, the assessment timelines are suspended.
Share: Facebook LinkedIn Telegram
© 2024–2026 Ukrainian Veterinary Alliance. All rights reserved.